Skip to main content
Premium Trial:

Request an Annual Quote

Patents Held by Benitec, Collaborator Allowed in US, South Korea, China

Premium

Benitec Biopharma said this week that the US Patent and Trademark Office has granted a patent from the company’s core Graham intellectual property portfolio.

Additionally, the company said it has received a South Korean patent related to its lead hepatitis C drug candidate TT-034, while a collaborator on its non-small cell lung cancer program has been issued a patent related to the use of RNAi to sensitize treatment-resistant lung cancer cells.

The US patent application, No. 20120135517, is entitled “Methods and Means for Obtaining Modified Phenotypes,” and claims DNA constructs targeting multiple genes with a broader range of length limitations on the sequence than in earlier patents, Benitec said. The constructs can also be used in a range of cells, including potentially stem cells.

The South Korean patent, which is owned by Benitec, is entitled “Multiple Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents,” the company noted.

The Chinese patent was issued to the University of New South Wales, and is entitled “Methods for Detecting and Modulating the Sensitivity of Tumor Cells to Anti-Mitotic Agents.”

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.